Drug Trial Radar · NCT06916806
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
May 5, 2027
Study completion Sep 15, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. • Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1), twice (Part 2a), or three times (Part 2b).
Conditions
- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathies
- Rheumatoid Arthritis
Interventions
AZD5492Drug
IMP: subcutaneous.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events.Time frame: Day 1 to end of the study (up to 52 weeks)
- Safety evaluation of AZD5492: Number of participants with related treatment-emergent adverse events.Time frame: Day 1 to end of the study (up to 52 weeks)
- Safety evaluation of AZD5492: Frequency of dose limiting toxicities (DLTs).Time frame: Day 1 to end of the study (up to 52 weeks)
- Safety evaluation of AZD5492: Number of SAEs leading to deathTime frame: Day 1 to end of the study (up to 52 weeks)
- Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events by grade.Time frame: Day 1 to end of the study (up to 52 weeks)
- Tolerability evaluation of AZD5492: Number of participants with treatment-emergent vital signs abnormalities.Time frame: Day 1 to end of the study (up to 52 weeks)
- Tolerability evaluation of AZD5492: Number of participants with treatment-emergent clinical laboratory abnormalities.Time frame: Day 1 to end of the study (up to 52 weeks)
- Tolerability evaluation of AZD5492: Number of participants with abnormal ECG.Time frame: From Day 1 up to Day 180
Locations
38 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Anniston, Alabama · Recruiting
Research Site
Birmingham, Alabama · Withdrawn
Research Site
La Jolla, California · Recruiting
Research Site
Sacramento, California · Not yet recruiting
Research Site
Iowa City, Iowa · Recruiting
Research Site
Omaha, Nebraska · Not yet recruiting
Research Site
Chapel Hill, North Carolina · Not yet recruiting
Research Site
Hamilton, Ontario, Canada · Recruiting
Research Site
Sherbrooke, Quebec, Canada · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Wuhan, China · Recruiting
Research Site
Zhengzhou, China · Recruiting
Research Site
Bordeaux, France · Recruiting
Research Site
Montpellier, France · Recruiting
Research Site
Nancy, France · Recruiting
Research Site
Paris, France · Recruiting
Research Site
Paris, France · Recruiting
Research Site
Strasbourg, France · Recruiting
Research Site
Toulouse, France · Recruiting
Research Site
Cologne, Germany · Recruiting
Research Site
Erlangen, Germany · Recruiting
Research Site
Magdeburg, Germany · Recruiting
Research Site
Pok Fu Lam, Hong Kong · Recruiting
Research Site
Bunkyō City, Japan · Recruiting
Research Site
Kita-gun, Japan · Recruiting
Research Site
Kitakyushu-shi, Japan · Recruiting
Research Site
Kyoto, Japan · Recruiting
Research Site
Nagasaki, Japan · Recruiting
Research Site
Amsterdam, Netherlands · Recruiting
Research Site
Leiden, Netherlands · Withdrawn
Research Site
Mérida, Spain · Recruiting
Research Site
Seville, Spain · Recruiting
Research Site
Valladolid, Spain · Recruiting
Research Site
Glasgow, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.